Portal de Periódicos da CAPES

The Immunofluorescent Tumor Imprint Technique

1966; American College of Physicians; Volume: 65; Issue: 1 Linguagem: Inglês

10.7326/0003-4819-65-1-9

1539-3704

Thomas K. Burnham,

Monoclonal and Polyclonal Antibodies Research

Article1 July 1966The Immunofluorescent Tumor Imprint TechniqueII. The Frequency of Antinuclear Factors in Connective Tissue Diseases and DermatosesTHOMAS K. BURNHAM, M.B., GERALD FINE, M.D., THOMAS R. NEBLETT, M.B., PH.D.THOMAS K. BURNHAM, M.B.Search for more papers by this author, GERALD FINE, M.D.Search for more papers by this author, THOMAS R. NEBLETT, M.B., PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-65-1-9 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAutoantibodies to nuclear and cytoplasmic constituents are characteristically present in connective tissue diseases or "autoimmune" processes. The lupus erythematosus (LE) cell test was the first practical demonstration of an antinuclear antibody that was found to be in the gamma globulin fraction of sera from patients with systemic lupus erythematosus (SLE) (1). With the advent of the indirect fluorescent antibody technique, more antinuclear factors became demonstrable. Antinuclear antibodies are present in the immunoglobulin classes, gamma 2 (gamma G or IgG), gamma 1A (gamma A or IgA), and gamma 1M (gamma M or IgM) (2) and lack organ and species specificity. Thus...References1. . Systemic lupus erythematosus. Amer. J. Med. 28: 416, 1960. CrossrefMedlineGoogle Scholar2. BARNETTNORTHCONDEMIJACOXVAUGHAN EVAFJJRFJH: Antinuclear factors in systemic lupus erythematosus and rheumatoid arthritis. Ann. Intern. Med. 63: 100, 1965. LinkGoogle Scholar3. BURNHAMFINENEBLETT TKGTR: Tumor imprints as a source of nuclear substrate for the detection of antinuclear factors. J. Invest. Derm. 43: 7, 1964. CrossrefGoogle Scholar4. BURNHAMNEBLETTFINE TKTRG: The immunofluorescent tumor imprint technique. I. Description and evaluation. Amer. J. Clin. Path. June 1966. CrossrefMedlineGoogle Scholar5. BECK JS: Variations in the morphological patterns of "autoimmune" nuclear fluorescence. Lancet 1: 1203, 1961. CrossrefMedlineGoogle Scholar6. BECK JS: Auto-antibodies to cell nuclei. Scot. Med. J. 8: 373, 1963. CrossrefMedlineGoogle Scholar7. LACHMANNKUNKEL PJHG: Correlation of antinuclear antibodies and nuclear staining patterns. Lancet 2: 436, 1961. CrossrefMedlineGoogle Scholar8. FRIOU GJ: Immunofluorescence and antinuclear antibodies. Arthritis Rheum. 7: 161, 1964. CrossrefMedlineGoogle Scholar9. ANDERSONGRAYBECKBUCHANANMCELHINNEY JRKGJSWWAJ: Precipitating auto-antibodies in the connective tissue diseases. Ann. Rheum. Dis. 21: 360, 1962. CrossrefMedlineGoogle Scholar10. CASALSFRIOUTEAGUE SPGJPO: Specific nuclear reaction pattern of antibody to DNA in lupus erythematosus sera. J. Lab. Clin. Med. 62: 625, 1963. MedlineGoogle Scholar11. BECK JS: Partial identification of the "speckled" nuclear antigen. Lancet 1: 241, 1962. CrossrefMedlineGoogle Scholar12. HALLBARDAWILBAYLESMEDNISGALINS APWATBADN: The relations between the antinuclear rheumatoid and L.E.-cell factors in the systemic rheumatic diseases. New Eng. J. Med. 263: 769, 1960. CrossrefMedlineGoogle Scholar13. ALEXANDERBREMNERDUTHIE WRJMJJ: Incidence of the anti-nuclear factors in human sera. Ann. Rheum. Dis. 19: 338, 1960. CrossrefMedlineGoogle Scholar14. BECKANDERSONGRAYROWELL JSJRKGNR: Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet 2: 1188, 1963. CrossrefMedlineGoogle Scholar15. RASKIN J: Fluorescent antibody studies of certain dermatoses. Arch. Derm. (Chicago) 89: 569, 1964. CrossrefMedlineGoogle Scholar16. POLLAK VE: Antinuclear antibodies in families of patients with systemic lupus erythematosus. New Eng. J. Med. 271: 165, 1964. CrossrefMedlineGoogle Scholar17. HASKERMACKAYMILLER JIRJJ: The incidence of "antinuclear factor" in human disease. Aust. Ann. Med. 14: 96, 1965. MedlineGoogle Scholar18. FENNELLRODNANVAZQUEZ RHGPJJ: Variability of tissue-localizing properties of serum from patients with different disease states. Lab. Invest. 11: 24, 1962. Google Scholar19. HARGRAVES MM: Systemic lupus erythematosus and L. E. cell phenomenon. Postgrad. Med. 16: 164, 1954. CrossrefGoogle Scholar20. SVECKAPLAN KHMH: A variant L.E. cell factor reactive only with "altered" nuclear material. Arthritis Rheum. 6: 11, 1963. CrossrefMedlineGoogle Scholar21. ROWELLBECK NRJS: Immunological abnormalities in 120 patients with apparent chronic discoid lupus erythematosus (abstract). Excerpta Med. 2: 1381, 1962. Google Scholar22. BURNHAM TK: Classification of lupus erythematosus. Lancet 1: 666, 1966. CrossrefGoogle Scholar23. CURTISJANSEN ACTG: The prognosis of localized scleroderma. Arch. Derm. (Chicago) 78: 749, 1958. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Detroit, MichiganFrom the Departments of Dermatology and Pathology and the Serology Laboratory, Henry Ford Hospital, Detroit, Mich.This paper was presented in part at the Section of Dermatology American Medical Association Meeting June 23, 1965, in New York, N. Y.Requests for reprints should be addressed to Thomas K. Burnham, M.D., Department of Dermatology, Henry Ford Hospital, Detroit, Mich. 48202. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntinuclear antibodies in dermatologyA PRAGMATIC APPROACH TO COST-EFFECTIVE USE OF LABORATORY TESTS AND IMAGING PROCEDURES IN PATIENTS WITH MUSCULOSKELETAL SYMPTOMSImmunopathogenesis of Systemic Sclerosis: Possible Role of RetrovirusesAutoantibodies Against Nuclear, Nucleolar, and Mitochondrial Antigens in Systemic Sclerosis (Scleroderma)Zellkernantigene bei systemischen Autoimmunkrankheiten: Molekulare Charakteristika und klinische BedeutungSystemic Lupus Erythematosus and SclerodermaAssociation between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disordersThe “true Speckled” antinuclear antibody (ANA) pattern: Its tumultuous historyAutoantibodies in Thromboangiitis Obliterans (Buerger's Disease)Autoimmune Retrobulbar Optic NeuritisMusculoskeletal Abnormalities of the Ten-Year Hemodialysis PatientAutoantibodies to Nuclear Antigens (ANA): Their Immunobiology and MedicineUtility of the Fluorescent Antinuclear Antibody Test in a Single PatientBRUCE RICHARDSON, M. D., Ph.D., WALLACE V. EPSTEIN, M.D.Immunologic tests of value in diagnosisHuman Antibodies to RNA-Containing ParticlesCharacteristics of antinuclear antibodies in rheumatoid. arthritisAnalysis of a large pedigree with elliptocytosis, multiple lipomatosis, and biological false-positive serological test for syphilisCardiopulmonary Manifestations of Progressive Systemic SclerosisVitiligo and morphoeaA controlled study of ana+ rf‐ arthritisPattern of antinuclear autoantibodies in diseases with systemic connective tissue lesionsAntinuclear antibodies (ANA): Immunologic and clinical significanceDermatomyositis (DM), Polymyositis (PM)Autoimmune Diseases of the Skin and Skin Disorders with Diverse Immuno-Pathological AbnormalitiesAntinuclear Antibodies and Anti-DNA-Antibodies in Connective Tissue Diseases and the Other Miscellaneous DiseasesAntinuclear Antibodies. I. Patterns of Nuclear ImmunofluorescenceTwo Epidermal Cytoplasmic Immunofluorescent Patterns Detected by Indirect ImmunofluorescenceLupus ErythematosusPLASMA-CORTISOL AND IMMUNOSUPPRESSION IN PROTEIN-CALORIE MALNUTRITIONANTINUCLEAR ANTIBODIES IN PATIENTS WITH MALIGNANCIESConnective Tissue DiseasesDNA antibodies in childhood sclerodermaAntinucleolar AntibodiesImmunofluorescent Techniques in Clinical Diagnosis of Cutaneous DiseaseDONALD M. KAY, M.D., DENNY L. TUFFANELLI, M.D., F.A.C.P.IMMUNOFLUORESCENT ANTIBODY STUDIES IN DERMATITIS HERPETIFORMISSignificance of nuclear immunofluorescent patterns.Detection by immunofluorescenge of antibodies specific for human malignant melanoma cellsSerum antinuclear antibodies in progressive systemic sclerosis (scleroderma)Untersuchungen zur Bedeutung des Fluoreszenz-Antiglobulintests und des Antiglobulin-Konsumptionstests zum Nachweis antinukleärer SerumfaktorenThe clinical significance of titered antinuclear antibodies 1 July 1966Volume 65, Issue 1Page: 9-19KeywordsAntinuclear antibodiesDermatologyGlobulinsLupus erythematosusNeutrophilsResearch laboratoriesSclerodermaSerologySkin diseasesSpecificity Issue Published: 1 July 1966 PDF downloadLoading ...